Upcoming Stories
California CRE News In Your Inbox .

California   /   April 23, 2021

Lisa Brown
By: Lisa Brown

Persephone is Committed to Diversity Inclusion with COVID Study

San Diego-based Persephone Biosciences Inc., a microbiome-focused biotechnology company, recently announced the initiation of the VOICES clinical study to determine the impact of gut microbiome composition and function on the immune system and efficacy of COVID-19 vaccination. VOICES  or Vaccine Observation to Include all Communities for Equitable Science is a single-site national study that will enroll up to 10,000 people being administered a COVID-19 vaccine. The study is vaccine-agnostic, meaning any vaccine currently or eventually authorized for emergency or other use in the U.S. by the Food and Drug Administration during the course of the VOICES study will be included.

The study will collect samples prior to and after subjects are vaccinated for the SARS CoV-2 virus, with the goal of identifying and determining specific gut microbiota and the metabolic processes that are involved in optimal immune response and function.

Persephone Biosciences is committed to diversity inclusion within the study, with a goal of balanced gender enrollment as well as 50 percent ethnic and racial minorities, as those populations have been disproportionately adversely impacted by COVID-19. The study will begin with an initial pilot study of a few hundred adults and scale to more than 10,000 participants nationwide.

Inside The Story
About the Author

Lisa Brown has more than 30 years of experience in corporate communications and marketing management with organizations including Grubb & Ellis, Marcus & Millichap and NAIOP.
Email the Author

New call-to-action
New call-to-action
New call-to-action
© ConnectCRE 2021 / 3900 San Fernando Road, Suite 1007, Glendale, CA 91204
Contact Us / Policies, Privacy & DisclosuresSubmit Press Release /